Results of posttreatment MRD assessment and correlation with PFS and survival in patients treated for relapsed/refractory or high-risk CLL
| Study . | Treatment . | No. patients tested for MRD (% MRD negative) . | MRD threshold, sample source, method . | PFS . | P value . | Survival . | P value . |
|---|---|---|---|---|---|---|---|
| Wierda et al 20055 | FCR | 32 with CR (38%) | Qualitative PCR, 10−5, BM | 27 vs 44 months (TTP) | NS | Not reported | NA |
| Moreton et al 200551 | Alemtuzumab | 34 with CR (53%) | 10−5, FLC BM | 20 months vs NR (TFS) | <.001 | 41 months vs NR | <.001 |
| Pettit et al 201250 | Alemtuzumab + HDMP | 25 (36%) | 10−4, FLC BM | Median 24 vs 10 months | .009 | Not reported | NA |
| Study . | Treatment . | No. patients tested for MRD (% MRD negative) . | MRD threshold, sample source, method . | PFS . | P value . | Survival . | P value . |
|---|---|---|---|---|---|---|---|
| Wierda et al 20055 | FCR | 32 with CR (38%) | Qualitative PCR, 10−5, BM | 27 vs 44 months (TTP) | NS | Not reported | NA |
| Moreton et al 200551 | Alemtuzumab | 34 with CR (53%) | 10−5, FLC BM | 20 months vs NR (TFS) | <.001 | 41 months vs NR | <.001 |
| Pettit et al 201250 | Alemtuzumab + HDMP | 25 (36%) | 10−4, FLC BM | Median 24 vs 10 months | .009 | Not reported | NA |
HDMP, high-dose methylprednisolone.